Opioid agonists produce analgesia in mammals through the activation of , , or ␦ opioid receptors. Previous behavioral and binding studies from our laboratory using an amphibian model suggested that , , or ␦ opioid agonists may activate a single type of opioid receptor in the grass frog, Rana pipiens. In the present study, kinetic, saturation, and competitive binding profiles for three opioid radioligands,
mentally derived values from saturation experiments gave affinity constants (K D ) in the low nanomolar range. The density of opioid binding sites (B max ) was 224.4, 118.6, and 268.9 fmol/mg for , , and ␦ opioid radioligands, respectively. The affinity values did not significantly differ among the three opioid radioligands, but the radioligand bound to significantly fewer sites than did the or ␦ radioligands. K i values for unlabeled , , and ␦ competitors, including highly selective opioid antagonists, were consistent with each radioligand selectivity profile. The present data suggest that , , and ␦ opioid radioligands bind to distinct opioid receptors in amphibians that are surprisingly similar to those found in mammalian brain.
Pharmacological studies show that opioids produce analgesia in mammals through the activation of one or more of three distinct types of opioid receptors. Evidence for the multiplicity of opioid receptors in mammals was first noted with behavioral studies (Martin et al., 1976) , was further confirmed by radioligand binding studies (Lord et al., 1977; Gillan et al., 1980) , and was verified through molecular cloning techniques identifying three types of opioid receptors, the , , and ␦ opioid receptors (Raynor et al., 1994) .
Although a triad of opioid receptors is known to mediate opioid analgesia in humans and other mammals, it is not known which type of opioid receptors mediate opioid antinociception in nonmammalian vertebrates. The antinociceptive effects of a number of opioid agonists were shown in an amphibian model using a behavioral assay, the acetic acid test (Pezalla, 1983; Stevens and Pezalla, 1983; Stevens, 1988) . The antinociception produced by these agents was shown to be opioid receptor-mediated as it was significantly blocked by the general opioid antagonists, naloxone and naltrexone (Stevens and Pezalla, 1984; Stevens et al., 1994) . Selective , , and ␦ opioid agonists cause dose-dependent, naltrexone-reversible antinociceptive effects following systemic or central administration (Stevens et al., 1994; Stevens, 1996; Stevens and Rothe, 1997) . Compared with results in mammals, the relative antinociceptive potency of selective , , and ␦ opioids is highly correlated following systemic and intraspinal administration in rodents and frogs (Stevens et al., 1994; Stevens, 1996) . Thus, the amphibian model serves as an adjunct model for the testing of opioid analgesics, with unique advantages and disadvantages (Stevens, 1992 (Stevens, , 1995 .
Recent binding studies from our laboratory characterized radioligand binding of the general opioid antagonist, [ 3 H]naloxone, in Rana pipiens brain and spinal cord tissue homogenates (Newman et al., 2000a,b) . Results using [ 3 H]naloxone revealed a single binding site in amphibian brain and spinal cord, which was displaced by , , and ␦ opioid ligands (Newman et al., 2000a,b) . The rank order of [ 3 H]naloxone displacement was Ͼ Ն ␦, which parallels the relative antinociceptive potency of selective opioid agonists (Stevens et al., 1994; Stevens, 1996; Stevens and Rothe, 1997) . Most unusual, the highly selective opioid antagonists, ␤-funaltrex-amine (␤-FNA), 17,17Ј-bis(cyclopropylmethyl)-6,6Ј,7,7Ј-tetrahydro-4,5,4Ј,5Ј-diepoxy-6,6Ј-(imino) [7,7Ј-bimorphinan ]-3,3Ј,  14,14Ј-tetrol dihydrochloride (nor-binaltorphimine, or nor-BNI), and naltrindole, displaced [ 3 H]naloxone with the same apparent affinity (K i ) of Ϸ3.0 nM in amphibian brain (Newman et al., 2000a) . Additionally, recent studies administering highly selective opioid antagonists with spinal administration of , , or ␦ opioid agonists revealed a striking difference between mammals and amphibians: the highly selective opioid antagonists, ␤-FNA (), nor-BNI (), and naltrindole (␦), were not selective in amphibians . In these behavioral studies, each selective opioid antagonist blocked the antinociceptive effects of selective , , or ␦ opioid agonists. It was important to get data on the binding of selective opioid agonists in R. pipiens to further our overall goal of characterizing the mechanisms of opioid antinociception in amphibians.
The selective opioid radioligands, (Gillan and Kosterlitz, 1982) , (Lahti et al., 1985; Kim et al., 1996) , and (Akiyama et al., 1985) were used previously to characterize opioid binding sites in a variety of vertebrate species (Gillan and Kosterlitz, 1982; Clark et al., 1988; Goldstein and Naidu, 1989; Deviche et al., 1993; Emmerson et al., 1994; Niwa et al., 1994; Darlison et al., 1997) . However, no studies thus far have systematically characterized selective opioid radioligand binding in the Northern grass frog, R. pipiens. Kinetic, saturation, and competitive binding experiments using three opioid radioligands, [ 3 H]DAMGO, [ 3 H]U69593, and [ 3 H]DPDPE, were completed in the present study. All three radioligands each bound with a best fit to a single-site model with high affinity and moderate receptor density. The binding affinity and receptor density of the sites labeled by each , , or ␦ opioid radioligand only differed in that there were significantly fewer sites detected. Compared with data obtained from mammalian studies, the sites labeled by the , , and ␦ opioid radioligands were surprisingly similar to those observed in mammals.
Materials and Methods
The following protocols using brain tissue harvested from the Northern grass frog, R. pipiens, were approved by the Institutional Animal Care and Use Committee in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. and 17-cyclopropylmethyl-6,7-dehydro-4,5-epoxy-3,14-dihydroxy-6,7,2Ј,3Ј- Crude membrane fractions from untreated frogs were prepared by decapitation followed by rapid excision of the brain. Tissue (wet weight average of 80 mg) was stored at Ϫ70°C until use in the binding assay. On the day of the experiment, tissue was thawed and homogenized in approximately 4 ml of 50 mM Tris-HCl with sodium EDTA, pH 7.4. Pellets were obtained by centrifugation of the homogenate at 400 rpm (29g) at 4°C for 15 min followed by centrifugation of the supernatant at 14,500 rpm (24,000g) at 4°C for 15 min. The resulting pellet was suspended in 12 ml of 50 mM Tris-HCl with 5 mM MgCl 2 (pH 7.4) and rehomogenized for immediate use in the binding assay. Mg 2ϩ was added to the buffer to increase agonist binding to high-affinity receptors (Rodriguez et al., 1982) . Protein content was determined with a spectrophotometer (Bradford, 1976 ) using bovine serum albumin as the standard (BioRad, Richmond, CA).
Binding Assay. Experiments were performed in triplicate, and the receptor-binding reactions were initiated by adding the radioligand of interest (50 l) to 400 l of tissue homogenate (brain; 0.09 -0.25 mg of protein) containing either 50 l of buffer (for total binding) or 50 l of unlabeled ligand for the determination of nonspecific binding. The components were incubated for 60 min at room temperature to attain steady state. Unbound ligand was separated from the receptor-ligand complex, and the binding reaction was terminated by rapid filtration using a Brandel (Gaithersburg, MD) 24-cell tissue harvester followed by washing (3 times at 5 ml for 15 s) with cold buffer onto Whatman (Clifton, NJ) GF/B glass-fiber filters that were presoaked for 1 h in 0.3% polyethylenimine to decrease nonspecific binding. Radioactivity was counted using a Beckman Coulter (Fullerton, CA) LS1801 scintillation counter (40 -50% efficiency) with Scintiverse scintillation fluid (Fisher Scientific, Pittsburgh, PA). Specific binding was defined as the difference between nonspecific binding (measured in the presence of excess 10 M concentrations of unlabeled drug; the same as the radioligand) and total binding. Kinetic Studies. The association component of kinetic analysis involved the addition of radioligand at various time points (10 measurements) where specific binding was measured. The dissociation component was accomplished by allowing the radioligand and homogenate to bind to equilibrium, at which point further binding was blocked by the addition of 10 M unlabeled agonist at various time points (10 measurements) where specific binding was measured.
Saturation and Competition Studies. Saturation analysis was performed by measuring specific binding over increasing concentrations of the respective radiolabeled agonist to determine receptor density (B max ) and affinity (K D ). Nonspecific binding was defined by a 10 M concentration of the respective unlabeled agonist. Competition binding experiments were performed using the respective radiolabeled agonist with increasing concentrations (15 steps) of various unlabeled ligands (0.01 nM-100 M). Binding reactions proceeded as described under Binding Assay. Each saturation analysis for each radioligand was carried out three times in triplicate.
Data Analysis. Kinetic, saturation, and competition analysis data were fit to two equations to compare one-and two-site models using nonlinear least-squares curves and are based on the statistical F-test (GraphPad Prism v3.0; GraphPad Software, San Diego, CA). For saturation analysis, the data were first fit to the rectangular hyperbolic function followed by linear transformation (Rosenthal plot of bound/free versus bound). Analysis of the rectangular hyperbola was used to obtain affinity (K D ) and density (B max ) data. In competition experiments, concentrations of unlabeled ligand that bound to half of the binding sites at equilibrium (K i ) were calculated by GraphPad using the correction of Cheng and Prusoff (1973) , which adjusts for the concentration of radioligand as well as the affinity of the radioligand for its binding site.
Results

Kinetics of Selective Radiolabeled Agonist Binding.
Kinetic analysis was performed to determine the time needed to attain a steady-state condition as well as the rate constants for association and dissociation (see Fig. 1 . These rate constants yielded a K D value of 1.23 nM. In all cases, statistical analysis of the comparison between one-and two-site models yielded a best fit for the one-site model (see Table 1 for results of F-test and significance).
Saturation Studies of Selective Opioid Agonist Binding. The properties of the selective agonist binding sites were studied over an extended range of concentrations of radiolabeled agonist, where apparent affinity and density data were determined. Saturation data for [ 3 H]DAMGO are shown in Fig. 2A , where a Rosenthal analysis of these data is shown in the inset. The experimentally derived K D and B max from saturation analysis were found to be 7.27 nM (2. Table 2 . In the case of all competitive ligands, the data were best fit to a one-site model as determined by the F-test.
Discussion
In the early days of opioid receptor investigation, amphibian brain tissues were used for receptor isolation and solubi- lization studies due to a great density of binding sites in nervous tissue and uniform characteristics (Simon et al., 1982 (Simon et al., , 1984 . Early binding studies confirmed opioid sites in amphibians but were limited by the unavailability of selective opioid agonists, antagonists, and radioligands (Pert et al., 1974; Buatti and Pasternak, 1981) . More recent studies focused on the binding of opioids in amphibian tissue; such work supports a 2 opioid receptor subtype (Benyhe et al., 1990a (Benyhe et al., ,b, 1992 . One study suggests that the amphibian opioid site is best described as a "non-, non-, non-␦" opioid receptor (Mollereau et al., 1988) . Other recent work suggests that 30% of binding sites are , 70% of sites are 2 , and no ␦ or 1 sites were detected in the giant toad, Bufo marinus (Brooks et al., 1994) . Using solubilization methods, other groups have characterized opioid sites in Rana esculenta as 70% , 17% , and 12% ␦ (Simon et al., 1984) .
The present study is the first systematic examination of binding sites for , , and ␦ opioid radioligands in R. pipiens brain tissue. These data are important because this amphibian species is well studied with regard to opioid antinociception. Each selective opioid radioligand bound to a single, high-affinity site and was displaced best by cognate agonists and antagonists. The binding affinity of the three selective opioid radioligands determined from saturation analysis did not differ from each other. However, there were significantly fewer binding sites than or ␦ sites. Previous studies from our laboratory showed that the nonselective opioid antagonists [
3 H]naloxone and [ 3 H]diprenorphine bound to a single, high-affinity site in amphibian brain and spinal cord (Newman et al., , 2000a . In these studies, the selective opioid antagonists ␤-FNA, nor-BNI, and NTI had equal affinity for the [ 3 H]naloxone site with K i values of about 3.0 nM each. This finding suggested that either there were three separate opioid sites for which ␤-FNA, nor-BNI, and NTI displaced [
3 H]naloxone with the same affinity or that the three antagonists displaced [ 3 H]naloxone at a single site (Newman et al., 2000a,b) . Additionally, behavioral data in R. pipiens demonstrated a lack of selectivity for ␤-FNA, nor-BNI, and NTI in blocking antinociception following administration of selective , , and ␦ opioid agonists . This led to the working hypothesis of an opioid unireceptor mediating the antinociceptive effects of , , and ␦ opioid agonists in amphibians (Stevens, 1998) . The present binding data and preliminary data from cloning studies (see below) do not support this unireceptor hypothesis. As mentioned above, initial binding studies using the nonselective opioid antagonist [
3 H]naloxone yielded data that did not discriminate multiple binding sites, and the selective opioid antagonists displaced naloxone with equal affinities (Newman et al. 2000a ). The present results using selective , , and ␦ agonist radioligands show that agonist binding does discriminate multiple binding sites and that selective opioid antagonists displace their cognate agonist radioligand as expected. This discrepancy between previous naloxone binding data and the present agonist binding data may be due to different binding assay conditions (100 mM NaCl in the antagonist buffer; 5 mM MgCl 2 in the agonist buffer) or a different number of sites available to bind antagonist and agonists in amphibian brain. Further studies are needed to clarify the differences seen in the binding of antagonist and agonist opioid radioligands and the selectivity of ␤-FNA, nor-BNI, and NTI in amphibians.
Affinity of , , and ␦ Radioligands for Amphibian Opioid Binding Sites. Determination of binding affinity for each radioligand by kinetic and saturation experiments gave similar results (Table 1 ). The radioligand, DAMGO, had an apparent affinity of 7.27 nM in saturation studies using amphibian brain tissue. This value agrees with the affinity of [ 3 H]DAMGO of 7.49 nM using toad brain homogenates (B. marinus) previously reported (Brooks et al., 1994) . In mammalian brain tissue, the affinity of [ 3 H]DAMGO for opioid sites was similar, with reported values of 1.6 and 6.7 nM (Gairin et al., 1985; Werling et al., 1986) . The opioid radioligand, U69593, bound with an affinity of 6.81 nM, which is consistent with the 15.3 nM value for [
3 H]U69593 saturation binding previously obtained using brain tissue from the European water frog, R. esculenta (Benyhe et al., 1992) . However, the affinity of [ 3 H]U69593 in the present study appears lower than that obtained in rodent brains, where K D values range from 0.86 to 2.7 nM (Lahti et al., 1985; Smith et al., 1989; Boyle et al., 1990; Bowen et al., 1992) . The ␦ opioid radioligand, DPDPE, bound with a K D of 4.69 in the present study. The binding of [ 3 H]DPDPE was not detected in toad brain (Brooks et al., 1994) . Consistent with the present results, the affinity of [ 3 H]DPDPE in saturation studies using mammalian brain tissue was 1.6 nM (Cotton et al., 1985) . In general, comparisons of the radioligand binding in amphibians and mammals reveal that affinity for and ␦ opioid radioligands is not significantly different in these two classes of vertebrates but that the opioid radioligand appears to bind with lower affinity in amphibian tissue. Density of , , and ␦ Opioid Binding Sites in Amphibian Brain. In amphibian whole brain tissue homogenates, the densities of and ␦ opioid binding sites were not significantly different from each other (regarding the 95% confidence intervals in Table 1 ), but the sites labeled by the radioligand were significantly fewer. Thus, the proportion of sites labeled by the three radioligands was about 37% for , 20% for , and 43% for ␦ radioligands. Using a blocking technique to determine the contribution of , , and ␦ sites to total [ 3 H]naloxone binding sites and receptor protection methods, previous studies in amphibians gave an estimate of 70 to 80% , 10 to 20% , and 0 to 10% ␦ sites in R. esculenta brain (Simon et al., 1984; Zawilska et al., 1988) . In toad brain, 30% of binding sites are , 70% of sites are 2 , and no ␦ or 1 sites were detected in the giant toad, B. marinus (Brooks et al., 1994) . The discrepancy in , , and ␦ radioligand binding densities between these studies and the present one may lie with differences in the methodology, the species of amphibian used, and the less selective opioids used in some of the previous studies.
Studies systematically examining , , and ␦ radioligand binding in rodent whole brain homogenates consistently show significant differences in the density of , , and ␦ binding sites (Gillan and Kosterlitz, 1982; Pfeiffer et al., 1982; Lahti et al., 1985; Toll et al., 1998) . In general, whole brain studies in mammals show a greater density of sites than or ␦ sites and usually more than ␦ sites. In the present studies using amphibians, and ␦ sites had about equal densities, and sites were significantly fewer. Within specific mammalian brain regions, this generality breaks down with regions displaying only one or two types of opioid binding sites, or all three (Mansour et al. 1988) . Discrete regions of amphibian brain were not examined for possible heterogeneity of opioid binding site distribution.
Displacement of , , and ␦ Radioligand Binding by Selective Opioid Agents. The selectivity of binding sites labeled by , , and ␦ radioligands was determined by cold competition experiments using the selective opioid agonists DAMGO, morphine, DPDPE, deltorphin, U69593, and CI977. Competition analyses of selective opioid agonists for the selective radiolabeled agonists revealed similarities to mammalian studies. That is, among the , , and ␦ opioids tested against [
3 H]DAMGO, agents with established opioid actions most effectively blocked the binding of [ 3 H]DAMGO, where DAMGO itself yielded a K i value of 12.2 nM (see Table  2 ). The highly selective antagonists for , , and ␦ opioid receptors yielded K i values ranging from 2.91 nM for ␤-FNA to 13 M for naltrindole against (Table 2) .
One strategy to compare the selectivity profile of these highly selective agonists is to compile a selectivity index, which is expressed as the ratio of selective opioid K i values in displacing two selective radiolabeled ligands, for example: Table 3 . In the series, the most notable finding was the selectivity of ␤-FNA, which was greater than 2000-fold compared with binding but was only 33-fold higher relative to ␦ binding. This is interesting considering that in mammals, ␤-FNA is known to have an initial agonist action in the mammal, whereas in the amphibian no agonist action is seen for ␤-FNA Tables 2 and 3 . DAMGO displays similar selectivity profiles with respect to ␦ (216-fold) and (128-fold) binding, whereas morphine shows a dramatic 5000-fold higher selectivity relative to and is only 6-fold that of ␦ binding. The lower selectivity for relative to ␦ might be expected considering that morphine is shown to be somewhat ␦ selective in mammals. Examining the series of selectivity, U69593 exhibits selectivity of 387-and 2332-fold compared with its affinity at ␦ and sites, respectively. CI977 shows 700-fold selectivity for binding relative to ␦ and 70-fold selectivity compared with binding. A ␦ selectivity profile was also done and most notable is NTI, which shows 5000-fold selectivity for ␦ relative to and only 2.83-fold for ␦ compared with . Overall, as was observed in the rhesus monkey (Emmerson et al., 1994) , each selective agonist shows superior selectivity for its respective opioid binding site relative to the other two opioid binding sites.
Opioid Antinociception and , , and ␦ Opioid Binding in Amphibians. Previous behavioral data on raising nociceptive thresholds following administration of , , and ␦ selective agonists demonstrated that the relative potency of selective opioids was highly correlated to the relative potency of analgesia obtained in mammals, including humans (Stevens, 1996; Stevens et al., 1994; Stevens and Rothe, 1997) . Present binding studies provide the initial characterization of opioid sites to complement these behavioral data. The present data show that selective opioid radioligands are displaced by selective opioids in a rank order generally consistent with their analgesic effects in mammals and antinociceptive effects in amphibians. However, because the same selective opioids used in the present binding study were tested for antinociceptive effects only after intraspinal administration in amphibians (Stevens, 1996) , correlative studies integrating behavioral and binding data will await the completion of radioligand binding studies using R. pipiens spinal cord tissue (studies in progress). Additionally, binding studies only provide information of the initial drug-receptor interaction; opioid agonists ultimately produce their pharmacological effects by activation of heterotrimeric G proteins. For this reason, data from GTP␥S binding in the presence of selective opioid agonists and antagonists are forthcoming and crucial to integrating behavioral and binding data.
Opioid Receptors in Amphibians and Mammals. Binding studies provide initial quantitative data on the affinity of a ligand for a putative receptor and an estimate on the number of receptors present. Definitive molecular evidence for amphibian opioid receptors is scant. To our knowledge and according to the online databases, the full sequence of an opioid-like receptor has not been cloned. However, earlier data of a 162-bp fragment obtained by degenerate primers designed from existing mammalian opioid receptors show that , , and ␦ opioid-like sequences are found throughout vertebrate phyla (Li et al., 1996) . Additionally, using the zebrafish (Danio rerio), -, -, and ␦-like receptors were cloned and functionally characterized Rodriguez et al., 2000) . We have also confirmed the earlier data of Evans and colleagues on three types of opioid receptor fragments among classes of vertebrates (Li et al., 1996) by cloning -, -, and ␦-like opioid receptor fragments from genomic DNA in R. pipiens (unpublished data).
Summary and Tentative Conclusions. The present data suggest that , , and ␦ opioid radioligands bind to distinct opioid receptors with the same affinity but that there are fewer sites than or ␦ sites. Furthermore, the sites labeled by the selective , , and ␦ radioligands show char- 
